Evidence map›Paper›PMID 23224295›Full record

ArticleInvestigational new drugs2013

Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kγ pathway.

V Sgnaolin, T C B Pereira, M R Bogo, R Zanin, A M O Battastini, F B Morrone, M M Campos

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Attenuation of pulmonary ACE2 activity impairs inactivation of des-ArgAmerican journal of physiology. Lung cellular and molecular physiology · 2018
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

V SgnaolinProstgraduate Program in Medicine and Health Sciences, Pontificia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6681, Partenon, 90619-900 Porto Alegre, RS, Brazil.
T C B Pereira
M R Bogo
R Zanin
A M O Battastini
F B Morrone
M M Campos
Pontifícia Universidade Católica do Rio Grande do Sul · BRUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kinins and their receptors have been recently implicated in cancer. Using functional and molecular approaches, we investigated the relevance of kinin B1 and B2 receptors in bladder cancer. Functional studies were conducted using bladder cancer cell lines, and human biopsies were employed for molecular studies. Both B1 des-Arg(9)-BK and B2 BK receptor agonists stimulated the proliferation of grade 3-derived T24 bladder cancer cells. Furthermore, treatment with B1 and B2 receptor antagonists (SSR240612 and HOE140) markedly inhibited the proliferation of T24 cells. Only higher concentrations of BK increased the proliferation of the grade 1 bladder cancer cell line RT4, while des-Arg(9)-BK completely failed to induce its proliferation. Real-time PCR revealed that the mRNA expression of kinin receptors, particularly B1 receptors, was increased in T24 cells relative to RT4 cells. Data from bladder cancer human biopsies revealed that B1 receptor expression was increased in all tumor samples and under conditions of chronic inflammation. We also show novel evidence demonstrating that the pharmacological inhibition of PI3Kγ (phosphatidylinositol 3-kinase) with AS252424, concentration-dependently reduced T24 cell proliferation induced by BK or des-Arg(9)-BK. Finally, the incubation of T24 cells with kinin agonists led to a marked activation of the PI3K/AKT and ERK 1/2 signaling pathways, whereas p38 MAP kinase remained unaffected. Kinin receptors, especially B1 receptors, appear to be implicated in bladder cancer progression. It is tempting to suggest that selective kinin antagonists might represent potential alternative therapies for bladder cancer.

Indexed as

AgedAged, 80 and overBiopsyBradykinin B1 Receptor AntagonistsBradykinin B2 Receptor AntagonistsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMiddle AgedPhosphatidylinositol 3-KinasesPhosphorylationProto-Oncogene Proteins c-aktReceptor, Bradykinin B1Receptor, Bradykinin B25-(5-(4-fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dioneBradykinin B1 Receptor AntagonistsBradykinin B2 Receptor AntagonistsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Bradykinin B1Receptor, Bradykinin B2Thiazolidinediones

Identifiers

PMID23224295
OpenAlexW2059329760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.